Canakinumab may prevent gout attacks

Unravelling shared mechanisms between CVD, diabetes, gout and renal disease

Interleukin-1-beta blockade with canakinumab reduces gout-attack rates without affecting serum uric acid levels, according to a post hoc analysis of clinical trial data.

"The consistent reduction in risk of approximately 50% across all of the baseline serum urate levels was surprising," said Dr Daniel Solomon from Brigham and Women's Hospital, in Boston, USA.

"One typically observes greater relative risk reductions with effective interventions among patients at higher risk. We observed similar relative risk reductions at all levels of baseline serum urate, which requires